Please login to the form below

Not currently logged in
Email:
Password:

MSD invests in FKD Therapies

MSD has taken an equity stake in the Finland based company, FKD Therapies, owned by former CEO of Ark Therapeutics Nigel Parker

MSD (known as Merck in the US and Canada) has taken an equity stake in the Finland based company, FKD Therapies. FKD Therapies, which has reserves of $16m, is a company started by Nigel Parker, the former chief executive of Ark Therapeutics.

This investment by MSD constitutes part of a deal that will see FKD Therapies develop MSD's gene therapy portfolio, which includes a possible treatment for bladder cancer.

The possible bladder treatment that FKD Therapies will be developing contains an adenovirus, which is designed to carry an interferon gene into the bladder wall cells. Here, it expresses a protein within the bladder, possibly increasing its ability to penetrate tumour cells.

MSD's gene therapy programmes for glaucoma surgery failure and the treatment of solid tumours were also available to develop.

20th September 2011

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Page & Page

Page & Page is a new kind of marketing communications consultancy. We change beliefs and behaviours to improve health outcomes...

Latest intelligence

The UK’s new five-year pricing agreement
Pharma has agreed to capped growth again - in exchange for uptake promises...
Digital applications are transforming the market access landscape
Organisations are leveraging new technology to implement a wider range of business models and, in essence, drive market access success by working smarter, faster and with greater economy....
Escaping the spin cycle of sub-optimal launch
...

Infographics